The mechanism of the PPARG agonists’ protection of full-course DR may be dependent on the glucose-lowering effect. Data are available in a public, open access repository. All data used in this study ...

In mice, the PPARG (γ2) knock-in resulted in increased PPARγ2 protein expression in adipocytes, confirming the functional relevance of the modification and highlighting its potential ...

Background: FX-909, a PPARG inverse agonist, is being evaluated in a first-in-human, dose escalation and expansion study in patients with advanced urothelial carcinoma (UC; NCT05929235). PPARG drives ...

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the February 2025 issue of British Journal of Ophthalmology by Cao et al.

Roche and Flare Therapeutics are igniting a partnership worth more than $1.8 billion in biobucks with hopes of discovering new small molecule cancer treatments via previously undruggable ...

Vladimir Putin declares truce in Ukraine - but how many times has he broken ceasefire agreements? Eromanga Rodeo brings together flood-affected communities Max Verstappen offered £226m to leave ...

However, PPARG expression in CESC and LGG is significantly different only in certain clinical features, such as the race of the patient in CESC and histological subtypes and TP53 mutation status in ...

We developed and characterized a novel human luciferase reporter cell line for the assessment of peroxisome proliferator-activated receptor γ (PPARγ) transcriptional activity, PAZ-PPARg. The ...

PPARG target genes including FABP4/Fabp4, AGT/Agt, IVT/Ivd and ARG1/Arg1 are repressed across different species and/or tissues, exemplified by dose-dependent suppression of FABP4/Fabp4 (a target gene ...

Flare Therapeutics today highlighted the first preclinical data from its lead compound FX-909, a novel, small molecule peroxisome proliferator-activated receptor gamma (PPARG) inhibitor to potentially ...

The money will be used to launch the company’s first clinical trial assessing FX-909, a small-molecule inhibitor targeting the PPARG transcription factor in patients with advanced urothelial cancer.

PPARG amplification, including a gain of only one copy number, is associated with higher PPARG expression PPARG expression levels were sustained in metastatic lesions compared locally advanced ...